Background: Finafloxacin is a novel 8-cyano-fluoroquinolone under investigation for treatment of urinary tract infection. Methods: Urinary concentrations and urinary bactericidal titers (UBT) of finafloxacin 200- and 800-mg single doses in 6 healthy volunteers were measured up to 48 h. UBT were determined for a reference strain and 9 selected clinical uropathogens at the pH of native, acidified (pH 5.5) and alkalinized (pH 8.0) urine. Results: The mean maximum urine concentrations for 200 and 800 mg finafloxacin were 69.3 mg/l (0–2 h) and 150 mg/l (4–8 h). Median UBT were between 0 and 1:>2,048 and were in general agreement with minimal inhibitory concentrations of strains and urinary pH values. UBT in alkaline urine were significantly lower than those in native or acidic urine, except for Enterococcus faecalis. Conclusions: Finafloxacin exhibited significant bactericidal activity against susceptible uropathogens. The urinary bactericidal activity of finafloxacin was enhanced in acidic urine and significantly lower in alkaline urine.

Keywords:
Finafloxacin, Urine pharmacokinetics, Pharmacodynamics, Urinary bactericidal titers
1.
Bedenic B, Topic M, Budimir A, Bubonja M: Urinary bactericidal activity of oral antibiotics against common urinary tract pathogens in an ex vivo model. Chemotherapy 2006;52:293–297.
2.
Kahlmeter G: An international survey of the antimicrobial susceptibility of pathogens from uncomplicated urinary tract infections: the ECO.SENS Project. J Antimicrob Chemother 2003;51:69–76.
3.
Naber KG, Schito G, Botto H, Palou J, Mazzei T: Surveillance study in Europe and Brazil on clinical aspects and Antimicrobial Resistance Epidemiology in Females with Cystitis (ARESC): implications for empiric therapy. Eur Urol 2008;54:1164–1175.
4.
Naber KG, Well M, Hollauer K, Kirchbauer D, Witte W: In vitro activity of enoxacin versus ciprofloxacin, fleroxacin, lomefloxacin, ofloxacin, pefloxacin, and rufloxacin against uropathogens. Chemotherapy 1998;44:77–84.
5.
Wagenlehner FM, Niemetz AH, Weidner W, Naber KG: Spectrum and antibiotic resistance of uropathogens from hospitalised patients with urinary tract infections: 1994–2005. Int J Antimicrob Agents 2008;31(suppl 1):S25–S34.
6.
Stamm W: Treatment of acute uncomplicated urinary tract infection; in Bergan T (ed): Urinary Tract Infections. Basel, Karger, 1997, vol 1, pp 1–7.
7.
Eliopoulos GM, Eliopoulos CT: Activity in vitro of the quinolones; in Hooper DC, Wolfson JS (eds): Quinolone Antimicrobial Agents. Washington, American Society for Microbiology, 1993, vol 2, pp 161–193.
8.
Naber K: Antibacterial activity of antibacterial agents in urine: an overview of applied methods; in Bergan T (ed): Urinary Tract Infections. Basel, Karger, 1997, vol 1, pp 74–83.
9.
Kresken M, Körber-Irrgang B, Labischinski H, Stubbings W: Effect of pH on the in vitro activity of finafloxacin against Gram-negative and Gram-positive bacteria (abstract No F1-2037). 48th ICAAC, Washington, 2008.
10.
Schubert S, Stubbings W, Dalhoff A: Comparative inhibitory and bactericidal activities of finafloxacin and ciprofloxacin against Gram-negative and Gram-positive UTI-pathogens under physiological conditions and at varying pH-values (abstract No F1-2041). 48th ICAAC, Washington, 2008.
11.
Higgins PG, Stubbings W, Wisplinghoff H, Seifert H: Activity of the investigational fluoroquinolone finafloxacin against ciprofloxacin-sensitive and -resistant Acinetobacter baumannii isolates. Antimicrob Agents Chemother 2010;54:1613–1615.
12.
Naber KG, Sörgel F: Antibiotic therapy: rationale and evidence for optimal drug concentrations in prostatic and seminal fluid and in prostatic tissue. Andrologia 2003;35:331–335.
13.
Patel H, Andresen A, Vente A, Heilmann HD, Stubbings W, Seiberling M, Lopez-Lazaro L, Pokorny R, Labischinski H: Human pharmacokinetics and safety profile of finafloxacin, a new fluoroquinolone antibiotic, in healthy volunteers. Antimicrob Agents Chemother, submitted.
14.
Wohlert SE, Jaetsch T, Gallenkamp B, Knops HJ, Lui N, Preisse M, Haebich D, Labischinski H: New fluoroquinolone finafloxacin HCl (FIN): route of synthesis, physicochemical characteristics and activity under neutral and acid conditions. 48th ICAAC, Washington, 2008.
15.
Naber KG, Theuretzbacher U, Kinzig M, Savov O, Sörgel F: Urinary excretion and bactericidal activities of a single oral dose of 400 milligrams of fleroxacin versus a single oral dose of 800 milligrams of pefloxacin in healthy volunteers. Antimicrob Agents Chemother 1998;42:1659–1665.
16.
Wagenlehner FM, Kinzig-Schippers M, Sörgel F, Weidner W, Naber KG: Concentrations in plasma, urinary excretion and bactericidal activity of levofloxacin (500 mg) versus ciprofloxacin (500 mg) in healthy volunteers receiving a single oral dose. Int J Antimicrob Agents 2006;28:551–559.
17.
Wagenlehner FM, Wydra S, Onda H, Kinzig-Schippers M, Sörgel F, Naber KG: Concentrations in plasma, urinary excretion, and bactericidal activity of linezolid (600 milligrams) versus those of ciprofloxacin (500 milligrams) in healthy volunteers receiving a single oral dose. Antimicrob Agents Chemother 2003;47:3789–3794.
18.
CLSI: Methods for dilution in antimicrobial susceptibility tests for bacteria that grow aerobically: approved guideline, ed 7. Approved Standard M7-A7. Wayne, Clinical and Laboratory Standards Institute, 2006.
19.
Griffith DP, Musher DM, Itin C: Urease: the primary cause of infection-induced urinary stones. Invest Urol 1976;13:346–350.
20.
Edberg S: The measurement of antibiotics in human body fluids: techniques and significance; in Lorian V (ed): Antibiotics in Laboratory Medicine. Baltimore, Williams & Wilkins, 1986, pp 466–467.
21.
Naber CK, Hammer M, Kinzig-Schippers M, Sauber C, Sörgel F, Bygate EA, Fairless AJ, Machka K, Naber KG: Urinary excretion and bactericidal activities of gemifloxacin and ofloxacin after a single oral dose in healthy volunteers. Antimicrob Agents Chemother 2001;45:3524–3530.
22.
Shah PM, Ottnad-Walz M, Stille W: In vitro activity of norfloxacin in synthetic media and human urine compared to that of cinnoxacin [sic!], nalidixic acid and pipemidic acid. Methods Find Exp Clin Pharmacol 1983;5:731–734.
23.
Shah PM, Ottrad M, Stille W: In vitro activity of norfloxacin in urine compared to that of cinnoxacin [sic!], nalidixic acid and pipemidic acid. Eur J Clin Microbiol 1983;2:272–274.
24.
Ambrose PG, Bhavnani SM, Rubino CM, Louie A, Gumbo T, Forrest A, Drusano GL: Pharmacokinetics-pharmacodynamics of antimicrobial therapy: it’s not just for mice anymore. Clin Infect Dis 2007;44:79–86.
25.
Andes D, Craig WA: Animal model pharmacokinetics and pharmacodynamics: a critical review. Int J Antimicrob Agents 2002;19:261–268.
26.
Craig WA: Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis 1998;26:1–10, quiz 11–12.
27.
Schentag JJ, Gilliland KK, Paladino JA: What have we learned from pharmacokinetic and pharmacodynamic theories? Clin Infect Dis 2001;32(suppl 1):S39–S46.
28.
Dalhoff A: Pharmacokinetics of selected antibacterial agents; in Schönfeld H (ed): Antibiotics and Chemotherapy. Basel, Karger, 1998, vol 49, pp 85–108.
29.
Karabalut N, Drusano GL: Pharmacokinetics of the quinolone antimicrobial agents; in Hooper DC, Wolfson JS (eds): Quinolone Antimicrobial Agents. Washington, American Society for Microbiology, 1993, vol 2, pp 195–223.
30.
Wagenlehner FM, Kinzig-Schippers M, Tischmeyer U, Wagenlehner C, Sörgel F, Naber KG: Urinary bactericidal activity of extended-release ciprofloxacin (1,000 milligrams) versus levofloxacin (500 milligrams) in healthy volunteers receiving a single oral dose. Antimicrob Agents Chemother 2006;50:3947–3949.
31.
Well M, Naber KG, Kinzig-Schippers M, Sörgel F: Urinary bactericidal activity and pharmacokinetics of enoxacin versus norfloxacin and ciprofloxacin in healthy volunteers after a single oral dose. Int J Antimicrob Agents 1998;10:31–38.
32.
Wagenlehner FM, Wagenlehner C, Redman R, Weidner W, Naber KG: Urinary bactericidal activity of doripenem versus that of levofloxacin in patients with complicated urinary tract infections or pyelonephritis. Antimicrob Agents Chemother 2009;53:1567–1573.
33.
Rohwedder R, Bergan T, Thorsteinsson SB, Scholl H: Transintestinal elimination of ciprofloxacin. Chemotherapy 1990;36:77–84.
34.
Cohen P: Effect of ciprofloxacin on growth of E coli in mouse bladder mucus (abstract No. 472). 18th Int Congr Chemother, Stockholm, 1993.
35.
Goh CY, Goh F, Stubbings W, Kroll H-P, Labischinski H: Bactericidal activity of finafloxacin against difficult to kill growth forms of Escherichia coli (abstract No. F1-2042). 48th ICAAC, Washington, 2008.
36.
Wagenlehner FM, Kinzig-Schippers M, Tischmeyer U, Wagenlehner C, Sörgel F, Dalhoff A, Naber KG: Pharmacokinetics of ciprofloxacin XR (1,000 mg) versus levofloxacin (500 mg) in plasma and urine of male and female healthy volunteers receiving a single oral dose. Int J Antimicrob Agents 2006;27:7–14.
37.
Boy D, Well M, Kinzig-Schippers M, Sörgel F, Ankel-Fuchs D, Naber KG: Urinary bactericidal activity, urinary excretion and plasma concentrations of gatifloxacin (400 mg) versus ciprofloxacin (500 mg) in healthy volunteers after a single oral dose. Int J Antimicrob Agents 2004;23(suppl 1):S6–S16.
© 2011 S. Karger AG, Basel
2011
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.